Allergan “Cedar” 150998-005

Status: Ongoing, but not recruiting

ClinicalTrials.gov Identifier: NCT02462928

150998-005: A Phase III, Multi-Center, randomized, double-masked, parallel group to assess the Safety and Efficacy of Abicipar compared to Ranibizumab in patients with Neovascular Age-Related Macular Degeneration.

Condition: Macular Degeneration

Study Type: Interventional

Duration: 104 weeks

Eligibility:

  • Ages: 50 years and older
  • Sexes: All
  • Accepts Healthy Volunteers: No

For additional information on this study, please click here

Go Back
This entry was posted in Uncategorized. Bookmark the permalink.